| FNH (focal nodular hyperplasia) is a benign lesion that is made up of hyperplastic hepatocytes isolated by fibrous septa and a central scar. FNH is most likely a product of a reaction. Following hemangioma, it is the most common benign liver lesion, and it normally occurs in normal liver parenchyma. It affects 0.3 percent to 6% of the general population , but the rate is rising, thanks in part to advances in radiological imaging. Different clinical and pathological characteristics affect the importance of distinguishing FNH from other hypervascular liver lesions such as hepatocellular adenoma (HCA), hepatocellular carcinoma (HCC), and hypervascular metastases, as appropriate care is crucial. FNH has a wide range of clinical signs and biochemical parameters.The aim of this study is to compare the efficacy of multi-phase multi-detector CT and MRI with the use of the hepatotropic contrast agent Gd-BOPTA in distinguishing FNH from other focal liver lesions (FLLs) in patients with equivocal foci on ultrasonography. The number of patients in final diagnosis in the non FNH group include 64 patients with HCC, HH with 105, Metastases in 7, HCA in 12 patients. Patients' age and lesion diameter were also statistically important differences: the mean age in the FNH group was 36 years (1856) vs 56 years (2179) in the non-FNH group (Z = 6.97, p 0.0001), and the mean diameter of a target in the FNH group was 37 mm (1085 mm) vs 29 mm (580 mm) in the non-FNH group (Z = 4.03, p 0.0001).All parameters had high interobserver reproducibility and consensus, with Kappa values of 0.851.0.In the differential diagnosis of FNH, MRI analysis with the administration of hepatotropic contrast agent is more successful than multi-phase multi-detector CT. Hepatotropic compounds allow for simultaneous evaluation of vascularization of focal changes and hepatocyte function (extracellular step and liver-specific analysis in the one-stop-shop examination).ddd |
